BMS-509744
Phase 2
Bristol-Myers SquibbBMS-509744 is one of 86 therapeutic programs targeting Inflammatory Bowel Disease. It is currently in Phase 2.
2
Indications
0
Total Trials
0
Active Trials
85
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Rituxan
RochePreclinical
Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BMS-509744. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company